The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer

[1]  M. Iorio,et al.  miR-9 and miR-200 Regulate PDGFRβ-Mediated Endothelial Differentiation of Tumor Cells in Triple-Negative Breast Cancer. , 2016, Cancer research.

[2]  M. Campiglio,et al.  CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers , 2016, Oncotarget.

[3]  O. Razorenova,et al.  CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer , 2016, Oncogene.

[4]  Wei Zhang,et al.  HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma , 2016, Tumor Biology.

[5]  M. Campiglio,et al.  Fhit Nuclear Import Following EGF Stimulation Sustains Proliferation of Breast Cancer Cells , 2015, Journal of cellular physiology.

[6]  D. Troyer,et al.  Dysregulated expression of cell surface glycoprotein CDCP1 in prostate cancer , 2015, Oncotarget.

[7]  H. Zhang,et al.  High throughput screening of cytokines, chemokines and matrix metalloproteinases in wound fluid induced by mammary surgery , 2015, Oncotarget.

[8]  A. Tinker,et al.  Elevated CDCP1 predicts poor patient outcome and mediates ovarian clear cell carcinoma by promoting tumor spheroid formation, cell migration and chemoresistance , 2015, Oncogene.

[9]  M. Mclaughlin,et al.  CUB-domain-containing protein 1 overexpression in solid cancers promotes cancer cell growth by activating Src family kinases , 2015, Oncogene.

[10]  M. Iorio,et al.  PDGFRβ and FGFR2 mediate endothelial cell differentiation capability of triple negative breast carcinoma cells , 2014, Molecular oncology.

[11]  J. Yokota,et al.  Oncogenic Ras/ERK Signaling Activates CDCP1 to Promote Tumor Invasion and Metastasis , 2014, Molecular Cancer Research.

[12]  Y. He,et al.  EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface , 2014, Oncogene.

[13]  H. Kato,et al.  In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling , 2014, Oncogene.

[14]  Zhonghua Zhao,et al.  Isolation and phenotypic characterization of colorectal cancer stem cells with organ-specific metastatic potential. , 2013, Gastroenterology.

[15]  E. Sonnhammer,et al.  Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. , 2013, The American journal of pathology.

[16]  H. Häring,et al.  Structural Requirements for Cub Domain Containing Protein 1 (CDCP1) and Src Dependent Cell Transformation , 2012, PloS one.

[17]  Francisco M. De La Vega,et al.  Genome and Transcriptome Sequencing in Prospective Metastatic Triple-Negative Breast Cancer Uncovers Therapeutic Vulnerabilities , 2012, Molecular Cancer Therapeutics.

[18]  M. Stack,et al.  The Cell Surface Glycoprotein CUB Domain-containing Protein 1 (CDCP1) Contributes to Epidermal Growth Factor Receptor-mediated Cell Migration* , 2012, The Journal of Biological Chemistry.

[19]  C. Benes,et al.  The SRC-associated protein CUB Domain-Containing Protein-1 regulates adhesion and motility , 2012, Oncogene.

[20]  P. Pollock,et al.  Cellular Settings Mediating Src Substrate Switching between Focal Adhesion Kinase Tyrosine 861 and CUB-domain-containing protein 1 (CDCP1) Tyrosine 734* , 2011, The Journal of Biological Chemistry.

[21]  I. Weissman,et al.  VHL loss in renal cell carcinoma leads to up-regulation of CUB domain-containing protein 1 to stimulate PKCδ-driven migration , 2011, Proceedings of the National Academy of Sciences.

[22]  M. Bui,et al.  A review of triple-negative breast cancer. , 2010, Cancer control : journal of the Moffitt Cancer Center.

[23]  R. Sakai,et al.  CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation. , 2010, Cancer research.

[24]  N Harbeck,et al.  Triple-negative breast cancer--current status and future directions. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  J. Bergh,et al.  Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. , 2009, The American journal of pathology.

[26]  R. Sakai,et al.  Expression of CUB domain containing protein (CDCP1) is correlated with prognosis and survival of patients with adenocarcinoma of lung , 2009, Cancer science.

[27]  W. Jonat,et al.  Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling. , 2009, Cancer letters.

[28]  G. Tsujimoto,et al.  Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma , 2008, Journal of Cancer Research and Clinical Oncology.

[29]  J. Yokota,et al.  CUB Domain-Containing Protein 1 Is a Novel Regulator of Anoikis Resistance in Lung Adenocarcinoma , 2007, Molecular and Cellular Biology.

[30]  R. Seger,et al.  The extracellular signal-regulated kinase: Multiple substrates regulate diverse cellular functions , 2006, Growth factors.

[31]  C. Craik,et al.  Adhesion signaling by a novel mitotic substrate of src kinases , 2005, Oncogene.

[32]  C. Benes,et al.  The C2 Domain of PKCδ Is a Phosphotyrosine Binding Domain , 2005, Cell.

[33]  W. Carter,et al.  Adhesion or Plasmin Regulates Tyrosine Phosphorylation of a Novel Membrane Glycoprotein p80/gp140/CUB Domain-containing Protein 1 in Epithelia* , 2004, Journal of Biological Chemistry.

[34]  M. Campiglio,et al.  Role of HER2 in wound-induced breast carcinoma proliferation , 2003, The Lancet.

[35]  E. Giannoni,et al.  New perspectives in PDGF receptor downregulation: the main role of phosphotyrosine phosphatases. , 2002, Journal of cell science.

[36]  P. V. van Diest,et al.  Expression of growth factors, growth‐inhibiting factors, and their receptors in invasive breast cancer. II: Correlations with proliferation and angiogenesis , 1998, The Journal of pathology.

[37]  B. Elliott,et al.  Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[38]  N. Davidson,et al.  Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[39]  宮澤 悠里.  CUB domain-containing protein 1, a prognostic factor for human pancreatic cancers, promotes cell migration and extracellular matrix degradation , 2010 .

[40]  C. Benes,et al.  The C2 domain of PKCdelta is a phosphotyrosine binding domain. , 2005, Cell.

[41]  L. Seymour,et al.  Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer , 2004, Breast Cancer Research and Treatment.